Beta Bionics, Inc. announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S., marking a significant expansion of the companies' existing collaboration in diabetes management technology.
Revolutionary Automated Insulin Delivery Technology
The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin dosing decisions automatically. This breakthrough technology enables people living with diabetes to achieve excellent clinical outcomes without the burden of carb counting or manual insulin correction calculations, though users must remain carb aware.
The system currently supports Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and the planned integration with the future dual glucose-ketone sensor will further enhance the platform's capabilities for comprehensive diabetes management.
Enhanced Real-Time Decision Support
"This integration holds great promise for further enhancing real-time decision-making support for people living with diabetes," said Sean Saint, President and CEO of Beta Bionics. "As the benchmark in automated insulin delivery systems, the iLet will naturally integrate with Abbott's future dual glucose-ketone sensor as soon as it becomes commercially available."
The collaboration reinforces both companies' shared commitment to bringing cutting-edge diabetes solutions to the market, building on their established partnership in glucose monitoring technology.
FDA-Cleared Innovation in Diabetes Care
Beta Bionics has developed the iLet Bionic Pancreas as the first FDA-cleared insulin delivery device with a fully autonomous insulin dosing algorithm. By leveraging advanced adaptive algorithms, the commercial-stage medical technology company has created a system designed to significantly enhance health outcomes and quality of life across a broad spectrum of individuals with diabetes.
The iLet sets a new standard in diabetes care by eliminating the complex calculations and constant monitoring traditionally required for insulin management, representing a paradigm shift toward fully automated diabetes treatment solutions.
